Kathleen M. Shannon

Best Publications

• Gut Microbiota Regulate Motor Deficits and Neuroinflammation in a Model of Parkinson’s Disease

  Timothy R. Sampson;Justine W. Debelius;Taren Thron;Stefan Janssen

  3629
  Citations

• A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease†

  C. Warren Olanow;Christopher G. Goetz;Jeffrey H. Kordower;A. Jon Stoessl

  1873
  Citations

• Increased Intestinal Permeability Correlates with Sigmoid Mucosa alpha-Synuclein Staining and Endotoxin Exposure Markers in Early Parkinson's Disease

  Christopher B. Forsyth;Kathleen M. Shannon;Jeffrey H. Kordower;Robin M. Voigt

  985
  Citations

• Prevalence of Parkinsonian Signs and Associated Mortality in a Community Population of Older People

  David A. Bennett;Laurel A. Beckett;Anne M. Murray;Kathleen M. Shannon

  907
  Citations

• Practice Parameter: Evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology

  D Aarsland;M Emre;A Lees;W Poewe

  639
  Citations

• Is alpha-synuclein in the colon a biomarker for premotor Parkinson's Disease? Evidence from 3 cases†‡§

  Kathleen M. Shannon;Ali Keshavarzian;Hemraj B. Dodiya;Shriram Jakate

  493
  Citations

• Role of TLR4 in the gut-brain axis in Parkinson’s disease: a translational study from men to mice

  Paula Perez-Pardo;Hemraj B Dodiya;Phillip A Engen;Christopher B Forsyth

  432
  Citations

• Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease

  Shannon Km;Bennett Jp;Friedman Jh

  400
  Citations

• A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease

  I. H. Richard;M. P. McDermott;R. Kurlan;J. M. Lyness

  396
  Citations

• Multicenter Study of Autologous Adrenal Medullary Transplantation to the Corpus Striatum in Patients with Advanced Parkinson's Disease

  Christopher G. Goetz;C. Warren Olanow;William C. Koller;Richard D. Penn

  331
  Citations

• Progression of intestinal permeability changes and alpha-synuclein expression in a mouse model of Parkinson's disease.

  Leo P. Kelly;Paul M. Carvey;Ali Keshavarzian;Kathleen M. Shannon

  324
  Citations

• Chronic stress-induced gut dysfunction exacerbates Parkinson's disease phenotype and pathology in a rotenone-induced mouse model of Parkinson's disease.

  Hemraj B. Dodiya;Christopher B. Forsyth;Robin M. Voigt;Phillip A. Engen

  302
  Citations

• Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia.

  C. L. Comella;J. Jankovic;K. M. Shannon;J. Tsui

  287
  Citations

• An R5L τ mutation in a subject with a progressive supranuclear palsy phenotype

  Parvoneh Poorkaj;Nancy A. Muma;Victoria Zhukareva;Elizabeth J. Cochran

  256
  Citations

• Clonidine and Gilles de la Tourette's syndrome: Double‐blind study using objective rating methods

  C G Goetz;C M Tanner;R S Wilson;V S Carroll

  216
  Citations

• Metric properties of nurses' ratings of parkinsonian signs with a modified Unified Parkinson's Disease Rating Scale

  D. A. Bennett;K. M. Shannon;L. A. Beckett;C. G. Goetz

  213
  Citations

• Effect of Creatine Monohydrate on Clinical Progression in Patients With Parkinson Disease A Randomized Clinical Trial

  Karl Kieburtz;Barbara C. Tilley;Jordan J. Elm;Debra Babcock

  207
  Citations

• The current clinical management of Huntington's disease.

  Wendy Phillips;Kathleen M. Shannon;Roger A. Barker

  194
  Citations

• Stereotactic pallidotomy for the treatment of Parkinson's disease Efficacy and adverse effects at 6 months in 26 patients

  K. M. Shannon;R. D. Penn;J. S. Kroin;C. H. Adler

  165
  Citations

• A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease

  Andrew McGarry;Michael McDermott;Karl Kieburtz;Elisabeth A. DeBlieck

  143
  Citations